Phase II Study For The Prevention Of Clinically Significant Adenovirus Adv, BK Virus BKV, Cytomegalovirus CMV, Epstein-Barr Virus EBV, Human Herpesvirus 6 HHV-6 And JC Virus JCV Infections Among Patients With No Viremia And/Or Disease In Patients With Detectable Viremia In Patients At High Risk For These Viruses Following Allogeneic Hematopoietic Cell Transplant HCT.
Study Type: Treatment
Phase: II
NCTID: NCT04693637
Principal Investigator:
Rajat Bansal